Effect of cerebrolysin in patients with ischemic stroke: A double-blind randomized control study

Authors

  • Seyed Ali Mousavi Department of Neurology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  • Azam Moradi Department of Neurology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  • Omid Mirmosayyeb Department of Neurology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran Medical Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran
  • Mansour Salehi Department of Cell and Molecular Biology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  • Fariborz Khorvash Department of Neurology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Keywords:

Cerebrolysin, ischemic stroke, neuroprotection

Abstract

We investigated the effect of cerebrolysin compared with placebo efficacy in patients with ischemic stroke. A total of 50 patients with ischemic stroke participate in this randomized double-blind placebo-controlled study. Patients were randomly divided into two groups; main group (n=25) was treated by 30cc IV cerebrolysin daily for 5 days. Control group (n=25) administrated 30 cc IV normal saline as a placebo daily during first five days of stroke attack. Three scoring system was used in the present study: National Institutes of Health Stroke Scale (NIHSS) on admission and after five days, and Barthel and Rankin’s scale after the 90 days. Data were analyzed by SPSS 16 using t-test. P-value less than 0.05 considered as significant level. The NIHSS score showed no significantly difference after 5 days (independent t-test, P = 0.195). There was a significant difference between Barthel and Rankin’s scale after 90 days (P = 0.039 and P = 0.008 respectively). In conclusion, cerebrolysin prevented the development of ischemic stroke’s sign and symptoms through 90 days.

Author Biographies

Seyed Ali Mousavi, Department of Neurology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Department of Neurology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Azam Moradi, Department of Neurology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Department of Neurology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Omid Mirmosayyeb, Department of Neurology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran Medical Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran

Department of Neurology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Medical Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran

Mansour Salehi, Department of Cell and Molecular Biology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Department of Cell and Molecular Biology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Fariborz Khorvash, Department of Neurology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Department of Neurology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

References

Clark WM, Wechsler LR, Sabounjian LA, Schwiderski UE. A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology 57:1595-1602, 2001.

De Keyser J, Sulter G, Luiten PG. Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing? Trends Neurosci. Dec ２２:535-540, 1999.

Martinez-Vila E, Sieira PI. Current status and perspectives of neuroprotection in ischemic stroke treatment. Cerebrovasc Dis 11:60-70, 2001.

Sacco RL, DeRosa JT, Haley EC, Jr., et al. Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: a randomized controlled trial. JAMA 285:1719-1728, 2001.

Bath PM, Sprigg N. Colony stimulating factors (including erythropoietin, granulocyte colony stimulating factor and analogues) for stroke. Cochrane Database Syst Rev 2:CD005207, 2007.

Gladstone DJ, Black SE, Hakim AM. Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke 33:2123-2136, 2002.

Muir KW, Lees KR. Excitatory amino acid antagonists for acute stroke. Cochrane Database Syst Rev 3:CD001244, 2003.

Savitz SI, Fisher M. Future of neuroprotection for acute stroke: in the aftermath of the SAINT trials. Ann Neurol 61:396-402, 2007.

Ladurner G, Kalvach P, Moessler H. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. J Neural Transm 112:415-428, 2005.

Goldstein LB, Samsa GP. Reliability of the National Institutes of Health Stroke Scale. Extension to non-neurologists in the context of a clinical trial. Stroke 28:307-310, 1997.

Mahoney FI, Barthel DW. Functional Evaluation: The Barthel Index. Md State Med J. Feb 1965;14:61-65.

van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19:604-607, 1988.

Lin SZ, Hoffer BJ, Kaplan P, Wang Y. Osteogenic protein-1 protects against cerebral infarction induced by MCA ligation in adult rats. Stroke 30:126-133, 1999.

Schabitz WR, Schwab S, Spranger M, Hacke W. Intraventricular brain-derived neurotrophic factor reduces infarct size after focal cerebral ischemia in rats. J Cereb Blood Flow Metab 17:500-506, 1997.

Lees KR, Zivin JA, Ashwood T, et al. NXY-059 for acute ischemic stroke. N Engl J Med 354:588-600, 2006.

Shuaib A, Lees KR, Lyden P, et al. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med 357:562-571, 2007.

Diener HC, Lees KR, Lyden P, et al. NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II Trials. Stroke 39:1751-1758, 2008.

Kawamata T, Dietrich WD, Schallert T, et al. Intracisternal basic fibroblast growth factor enhances functional recovery and up-regulates the expression of a molecular marker of neuronal sprouting following focal cerebral infarction. Proc Natl Acad Sci U S A 94:8179-8184, 1997.

Downloads

Published

2017-10-09

Issue

Vol. 4 No. 4 (2017)

Section

Articles

License

Authors who publish with the American Journal of Experimental and Clinical Resaerch (AJECR) agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY-NC-ND) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).